![]() However, the long-term effect of hormone therapy on MPV changes and the predictive role of MPV in thrombotic side effects have not been comprehensively studied in breast cancer. The relationship of MPV and platelets with cardiovascular and thrombotic events and their prognostic role have been demonstrated in many cancers. Although using AIs is associated with increased risk of fracture and musculoskeletal and genitourinary symptoms due to estrogen deprivation, potential adverse effects of AIs on cardiovascular events remain unclear. Cardiovascular events are relatively rare and serious side effects that are likely to be associated with AIs however, they are more common than that observed in patients receiving Tmx. Although Tmx is associated with increased incidence of deep vein thrombosis and endometrial cancer, which is due to partial agonistic effect of estrogen, the underlying cause of thrombovascular side effects has as yet not been clearly explained. Tamoxifen and AIs have several side effects. A high MPV value can also be expected as a result of vascular thrombotic events, such as myocardial and cerebral infarction. Many studies have suggested that a high MPV value is one of the risk factors for vascular diseases. Mean platelet volume (MPV) is frequently used to measure volumetric platelet size, which is considered a potential indicator of platelet reactivity. Platelet size and density may vary from person to person. Some large platelets are observed after coronary vascular events, and platelet size is a predictive marker for myocardial infarction and death. Large platelets have higher metabolic and enzymatic activities and are potentially more susceptible to thrombosis. Numerous studies have identified the role of platelets in the thrombosis process. Various genes, diseases, risk factors, and treatments affect platelet activation. Platelets are blood components that have an important in hemostasis as well as in thrombus formation and in the pathogenesis of atherosclerosis. AIs reduce the conversion of androgens to estrogens. Tmx is a selective estrogen receptor modulator that binds to hormone receptors. Five to ten years of adjuvant endocrine therapy, such as tamoxifen and aromatase inhibitors, is recommended for all hormone receptor positive early stage breast cancer patients. Most breast cancer patients are hormone receptor positive at diagnosis. Monitoring changes in MPV values may be predictive for severe side effects in breast cancer patients receiving hormone therapy. This is the first study evaluating the relationship between the 5-year adjuvant endocrine therapy and changes in MPV values in breast cancer patients. The mean MPV value was significantly increased in all patients in the Tmx, AI, and switch groups over time (p<0.001). ResultsĪll patients were females and their median age was 50 years (range, 27–78 years). MPV levels were measured at baseline and at the first and fifth year of hormone therapy. Methodsĭata of 261 patients who had pathologically confirmed estrogen or progesterone receptor positive invasive breast cancer and had received hormonotherapy for at least a 5-year period were retrospectively analyzed. The present study investigated the changes in MPV values of breast cancer patients receiving long-term adjuvant hormone therapy and the relationship of MPV with adverse effects of hormonotherapy. Tamoxifen (Tmx) and aromatase inhibitors (AIs), which are adjuvant endocrine therapies, may cause serious side effects, such as vascular thrombosis. Mean platelet volume (MPV) is a parameter that increases during thrombotic and cardiovascular events.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |